Drug interaction study reveals how carbamazepine alters zongertinib levels

NCT ID NCT06028464

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial in 16 healthy men tested how taking carbamazepine (a strong enzyme inducer) changes the amount of zongertinib in the blood. Participants received a single dose of zongertinib alone, then later took increasing doses of carbamazepine for 18 days followed by another zongertinib dose. The study measured drug levels to see if carbamazepine speeds up zongertinib breakdown, which could affect dosing in future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zongertinib and carbamazepine
What this could lead to: If successful, this study could help doctors understand how to adjust zongertinib doses when patients also take carbamazepine.
What could go wrong: This is a small, early-stage trial in healthy volunteers, not patients. Results may not directly apply to people with cancer or other conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Locations

CRS Clinical Research Services Mannheim GmbH

Mannheim, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.